Vigil Neuroscience is barreling forward with a strategy that will see it hop along steppingstones from rare diseases to Alzheimer’s. Having emerged with $50 million late last year, Vigil has gathered up an additional $90 million to validate its ex-Amgen asset in a rare, inherited neurodegenerative disease.
Kojin Therapeutics has raised $60 million to use iron-dependent cell death to treat drug-resistant cancer. The series A round positions the biotech to build on the work its scientific founders did at institutions including Harvard University and Dana-Farber Cancer Institute.
China’s Stemirna Therapeutics has raised RMB 1.2 billion ($188 million) to bankroll development of an mRNA vaccine against COVID-19. Sequoia Capital China co-led the financing with backers including WuXi AppTec plus assists from OrbiMed and other investors.
Stablix Therapeutics launches today with a $63 million series A to bankroll work on protein stabilization in the hopes of treating rare diseases, cancer and immunological disorders.
Clear Labs is looking to put down new roots in the fight against COVID-19 by pivoting its genomic testing tech previously aimed at catching salmonella and listeria before they reach the dinner table.